AbCellera is a cash-rich antibody-platform biotech where upcoming clinical catalysts could transform a depressed post-COVID valuation into a high-upside pipeline story.
Overview
AbCellera is a clinical-stage antibody platform company combining Trianni humanized mice, microfluidics, Celium AI, and in-house GMP manufacturing to discover and advance next-generation biologics. Its model blends research fees, milestones, royalties, licensing, and settlements, serving global pharma and biotech customers. The company is transitioning from COVID-era royalty dependence to a higher-upside internal pipeline and partnered-development model focused on oncology, immunology, endocrinology, and women’s health, with speed and difficult-target expertise as its core differentiation.